PER have announced its potentially pivotal Ph2b trial in DMD has now finalised recruitment with 48 non-ambulant boys now under study protocols.
This marks a significant achievement and crucially for investors, gives certainty on timeframes with the top-line readout flagged for December 2024.
With more certainty around timelines, we view potential for increased investor interest to enter the name in the months leading up alongside further safety tox data readouts due shortly after mid-year, and potential partnership activity.
We maintain our valuation of A$0.23 p/s and Speculative Buy recommendation, noting the high risk/return profile over the next 6 to 18 months as clinical results are released.
